428 related articles for article (PubMed ID: 34731142)
1. Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.
Wei M; Guo H; Liu S; Xu F; Zhang Y; Shi J; Xu Z; Chen Y
Medicine (Baltimore); 2021 Oct; 100(41):e27521. PubMed ID: 34731142
[TBL] [Abstract][Full Text] [Related]
2. Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma.
Yang Y; Liu Z; Wang H
Med Sci Monit; 2020 Jul; 26():e923716. PubMed ID: 32732863
[TBL] [Abstract][Full Text] [Related]
3. Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.
Cohen YC; Joffe E; Benyamini N; Dimopoulos MA; Terpos E; Trestman S; Held-Kuznetsov V; Avivi I; Kastritis E
Leuk Lymphoma; 2016; 57(6):1382-8. PubMed ID: 26727104
[TBL] [Abstract][Full Text] [Related]
4. [Significance of Lymphocyte-to-Monocyte Ratio and Corrected Levels of Serum Calcium as Prognostic Markers in Patients with Newly Diagnosed Multiple Myeloma].
Peng QY; Ma RJ; Guo RN; Zhang F; Li Y; Hu DM; Yao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):152-157. PubMed ID: 35123619
[TBL] [Abstract][Full Text] [Related]
5. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
7. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W
Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142
[TBL] [Abstract][Full Text] [Related]
8. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
9. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
[TBL] [Abstract][Full Text] [Related]
10. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant.
Sweiss K; Lee J; Mahmud N; Calip GS; Park Y; Mahmud D; Rondelli D; Patel PR
Bone Marrow Transplant; 2020 Jan; 55(1):199-206. PubMed ID: 31527821
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic Value of Immune Status Changes after Chemotherapy in Patients with Newly Diagnosed Multiple Myeloma].
Ma CC; Chai Y; Wang X; Xiang X; Gao Y; Hu WL; Chen HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1869-1875. PubMed ID: 31839052
[TBL] [Abstract][Full Text] [Related]
12. [Influence of Peripheral Blood Lymphocyte/Monocyte ratio (LMR) and Its Ratio to Lactate Dehydrogenase on Prognosis of Patients with Diffuse Large B-Cell Lymphoma].
Yang D; Su LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1563-1569. PubMed ID: 33067955
[TBL] [Abstract][Full Text] [Related]
13. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
14. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma.
Zhou X; Wang J; Xia J; Cheng F; Mao J; Zhu J; Guo H
Cancer Biomark; 2018; 22(1):43-48. PubMed ID: 29562497
[TBL] [Abstract][Full Text] [Related]
16. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
17. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M
Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698
[TBL] [Abstract][Full Text] [Related]
19. Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Kuroda J; Shimura Y; Ohta K; Tanaka H; Shibayama H; Kosugi S; Fuchida S; Kobayashi M; Kaneko H; Uoshima N; Ishii K; Nomura S; Taniwaki M; Takaori-Kondo A; Shimazaki C; Tsudo M; Hino M; Matsumura I; Kanakura Y;
Int J Hematol; 2014 Apr; 99(4):441-9. PubMed ID: 24584872
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Straka C; Knop S; Vogel M; Müller J; Kropff M; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Salwender H; Wandt H; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Fischer T; Liebisch P; Engelhardt M; Einsele H
Eur J Haematol; 2019 Sep; 103(3):255-267. PubMed ID: 31231828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
